Coredio

Coredio is a digital health company that has developed a software-as-a-medical-device (SaMD) platform known as the Cardiac Performance Simulation Engine (CPSE). The platform utilizes physics-informed artificial intelligence and personalized digital twins of a patient's cardiovascular system to estimate critical hemodynamic parameters—such as cardiac output, systemic vascular resistance, and central venous pressure—noninvasively. By integrating with consumer smartwatches and standard blood pressure cuffs, the technology aims to provide catheter-grade hemodynamic insights without the need for needles, implants, or invasive procedures. The company's approach involves a one-time calibration to create a patient-specific model, enabling ongoing remote monitoring through daily spot checks performed by patients in clinical or home settings.

This technology is designed to support cardiologists, primary care physicians, and nursing teams in heart failure management by providing continuous cardiovascular visibility between hospital visits. By allowing care teams to identify concerning trends early and adapt treatment plans based on individual patient data, Coredio seeks to improve quality of care, reduce hospital readmissions, and minimize the burden of invasive diagnostic procedures. The platform is intended to facilitate earlier, smarter clinical interventions, helping to bridge the gap between hospital-based measurements and at-home monitoring. The CPSE platform has received FDA Breakthrough Device Designation and has been accepted into the FDA’s Total Product Life Cycle Advisory Program (TAP).